Class Action Finder

Phenylpropanolamine (PPA) is used in prescription and over-the-counter drug products like nasal or sinus decongestants and weight-loss products.

The Food and Drug Administration (FDA) is in the process of removing PPA from all drug products and has asked all drug companies to discontinue marketing products containing PPA. The FDA has also issued a public health advisory concerning PPA.

In May 2000, the FDA received results of a Yale study that reflected an increased risk of hemorrhagic stroke (bleeding of the brain) in people who consumed PPA. The research showed that the number of people having strokes when taking PPA was more than the number of people having strokes who were not taking PPA. In response to this finding, pharmaceutical companies have since reformulated products to leave out PPA.

Though the risk of hemorrhagic stroke is low, FDA is still concerned because strokes are a serious affliction and it is difficult to predict who may be more prone to suffering such a condition.

Related posts:

1. Vioxx
2. Merck puts an end to state probes on Vioxx
3. Cholesterol drugs Zeta and Vytorin face class action suits

Categories: Pharmaceuticals
Tags: